Form 8-K - Current report:
SEC Accession No. 0001724521-23-000018
Filing Date
2023-11-07
Accepted
2023-11-07 16:04:38
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rcus-20231107.htm   iXBRL 8-K 28878
2 EX-99.1 a2023q38kexhibit991.htm EX-99.1 114304
6 img230044022_0a.jpg GRAPHIC 57792
  Complete submission text file 0001724521-23-000018.txt   362880

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rcus-20231107.xsd EX-101.SCH 1892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rcus-20231107_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rcus-20231107_pre.xml EX-101.PRE 12502
8 EXTRACTED XBRL INSTANCE DOCUMENT rcus-20231107_htm.xml XML 2908
Mailing Address 3928 POINT EDEN WAY HAYWARD CA 94545
Business Address 3928 POINT EDEN WAY HAYWARD CA 94545 (510) 694-6200
Arcus Biosciences, Inc. (Filer) CIK: 0001724521 (see all company filings)

EIN.: 473898435 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38419 | Film No.: 231383612
SIC: 2834 Pharmaceutical Preparations